Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-08-26

Clinical Trial Update: Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML [Phase 3]

View source ↗

Summary

Phase 3 study of BMS-354825 (nilotinib) in chronic-phase chronic myelogenous leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tasigna (nilotinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myeloid Leukemia, Chronic, Chronic-Phase | Phase 3 | Status: COMPLETED | Results posted: 2015-08-26